AI-Designed DNA Vaccine Aims for Broad Coronavirus Protection

Cambridge researchers used a machine-learning model to design a DNA-based vaccine targeting the sarbecovirus family (SARS, COVID and related viruses), creating a “super-antigen” and conducting the first human trial of an AI-designed vaccine. In a 39-person study, the vaccine activated virus-fighting antibodies and was well tolerated across four doses, but the immune response was modest and durability is unknown. If successful, the approach could provide broad protection against current and future coronavirus mutations, with the benefits of stability and needle-free administration, though more research is needed.